ML, Lillemoe TJ, Finkelstein MJ, Money JE, Susnik B, Grimm E, Kang SHL, Swenson
KK. Utility of Oncotype Dx® Risk Assessment in Patients with Invasive Lobular
Carcinoma. Clinical Breast Cancer. 2015
Aug 19 pii: S1526-8209 [Epub ahead of print].
LI, Zhao F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann
TM, Leach JW, O’Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Anxiety
and health-related quality of life among patients with low-tumor burden
non-Hodgkin lymphoma randomly assigned to two different rituximab dosing
regimens: results from ECPG trial E4402 (RESORT), J Clin Oncol. 2015 Mar 1;33(7):740-8.
I, Schilder RJ, Pippitt CH Jr, Wong S, Gordon AN, Scudder S, Kridelka F, Dirix
L, Leach JW, et al. A phase 1b study of trebananib in combination with
pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant
or partially platinum-sensitive ovarian cancer. Gynecol Oncol. 2014 Oct; 135(1): 25-33. [Epub ahead of print 2014
AM, Samavat H, Torkelson C, Bedell S, Wang R, Swenson KK, Wu AH, Ursin G, Le C,
Yuan JM, Kurzer MS. The safety of green tea extract supplementation in
postmenopausal women at risk for breast cancer: Results of the Minnesota Green
Tea Trial. Food Chem Toxicol. 2015
Sep;83:26-35. [Epub ahead of print].
RHI, Kaufman HL, Collichio F, Amatruda T, et al. Talimogene Laherparepvec
improves durable response rate in patients with advanced melanoma. J Clin Oncology 2015;33(25), 2780-2788.
[Epub ahead of print].
C, Economou S, Amatruda TT, Martin JC, Dudek AZ. Prognostic significance of
microscopic tumor burden in sentinel lymph node in patients with cutaneous
melanoma. Anticancer Research. 2015
S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmadi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA,
Tonetti DA. High incidence of triple negative breast cancers following
pregnancy and an associated gene expression signature. Springerplus. 2015 Nov 19; 4:710.
KA, Baldinger SR, Harris A, Sencer S, Messinger Y. Ovarian tumors related to
intronic mutations in DICER1: A report from the International Ovarian and
Testicular Stromal Tumor Registry. Familial
Cancer, 2015 Aug 20. [Epub ahead of print].
B, Day D, Abeln E, Bowman T, Krueger J, Swenson KK, Tsai ML, Bretzke ML,
Lillemoe T. Surgical outcome of lobular neoplasia diagnosed in core biopsy:
Prospective study of 316 cases. Clinical
Breast Cancer. 2016 Jun 14. Pii: S1526-8209(16)30145-8. [Epub ahead of
V, Michalowicz B, deJong E, Griffin T, Basi D, Hughes P, Tsai M, Swenson K,
Rockwell L, Gopalakrishnan R. Salivary proteomics in bisphosphonate-related
osteonecrosis of the jaw. Oral Dis.
Michalowicz BS, Hughes PJ, Basi DL, Tsai ML, Swenson KK, Rockwell L,
Gopalakrishnan R. Serum markers of bone turnover and angiogenesis in patients
with bisphosphonate-related osteonecrosis of the jaw after discontinuation of
long-term intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2016 Apr; 74(4):738-746.
2015 Oct 3.
Goy A, Forero A, Wagner-Johnston N, Ehmann C,
Tsai M, Hatake K, Ananthakrishnan R, Volkert A, Vandendries E, Ogura M. A phase
2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin
lymphoma refractory to rituximab alone, rituximab and chemotherapy or
radioimmunotherapy. Br J Haematol.
2016 Apr 22 doi: 10.1111/bjh.14094. [Epub ahead of print].
SK, Parker RJ, Leach JW, Hill MJ, Burgart LJ. Tumor histopathology predicts
outcomes after resection of colorectal cancer liver metastases treated with and
without pre-operative chemotherapy. J
Surg Oncol. 2016 Mar;113(4): 456-462. Epub 2016 Jan 12.
HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K,
Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in
melanoma patients treated with talimogene laherparepvec from a
multi-institutional phase II study. J
Immonother Cancer. 2016 Mar 15;4:12. eCollection 2016.
VJ, Seng JE, Leach J, Larson T, et al. Phase II study of
nab-Paclitaxel/Gemcitabine alternating with FOLFIRI and 1st line
therapy in patients with metastatic pancreatic cancer. Poster presentation at
the 2015 ASCO, Chicago, IL.
Kelly K , Leach J, et
al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic
or locally advanced solid tumors: assessment of safety and tolerability in a
phase I, open-label expansion study. Poster presentation at the 2015 ASCO,
Gulley J, Leach J.
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a
phase 1b, open-label expansion trial in patients progressing after
platinum-based chemotherapy. Poster presentation at the 2015 ASCO, Chicago, IL.
H, Amatruda T, Nemunaitis JJ, Chesney JA, Delman KA, Spitler LE, et al. Tumor
size and clinical outcomes in melanoma patients treated with talimogene
laherparepvec (T-VEC). Poster presentation at 2015 ASCO Annual Meeting, June 1,
2015, Chicago, IL.
A, Henn A, Shamsi N, Finkelstein M, Smith C, Reddy S, Min M, Ricci P. Outcome
of hepatic resection for hepatocellular carcinoma in patients without
cirrhosis. Poster presentation at the 2015 International Liver Cancer
Association Annual Conference, Sept 4-6,
2015, Paris, France.
ML, Finkelstein MJ, Lillemoe TJ, Susnik B, Grimm E, Kang, S-H, Kelly C, Swenson
KK. Evaluation of the pathologic predictors of treatment response to
neoadjuvant chemotherapy for invasive lobular breast cancer. Poster
presentation at the AACR: Advances in Breast Cancer Research Meeting, Bellevue,
WA, Oct 17-20, 2015.
J. Early clinical trials evaluating cell-based, checkpoint inhibitors and novel
immunotherapeutics. Podium presentation at the AACR Annual Meeting 2016 in New
Orleans, Louisiana, April 19, 2016.
J, Gode A, Kolste A, Reinstein A, Dusek J, Trebesch D, Migliori M, Johnson J,
Sendelback S. A pilot randomized controlled trial to assess the impact of
acupuncture on post-mastectomy pain, nausea, anxiety and ability to cope.
Poster presentation at the 40th Annual ONS Congress, Orlando, FL,
A, Skrypek M, Hansen M, Wein A, Kebriaei M, Baldinger S, Pacheco MC, Helseth P,
Bhambhani V, Crabb B. Case report of metastatic atypical teratoid rhabdoid
tumor (ATRT) secondary to an inherited germline mutation in the SMARCA4 gene:
literature review and recommendations for tumor surveillance of asymptomatic
carriers. Poster presentation at the International Symposium on Pediatric
Neuro-Oncology, LiverPool, England, June 12-15, 2016.
Overman M, Kopetz S, McDermott R, Leach J,
Lonardi S, Lenz H-J, Morse M, Desai J, Hill A, Axelson M, Moss RA, Lin C-S,
Goldberg M, Andre T. Nivolumab (N) ± ipilimumab (I) in treatment (tx) of
patients (pts) with metastatic colorectal cancer (mCRC) with and without high
microsatellite instability (MSI-H): CheckMate-142 interim results. Podium
presentation at the ASCO Annual Meeting, June 2016.
Hassan R, Thomas A, Patel M, Nemunaitis J,
Bennouna J, Powderly J, Taylor M, Dowlati A, Chen F, Leach J, Vaishampayan U,
Verschraegen C, Delord JP, Grote HJ, von Heydebreck A, Cuilerot JM, Gulley JL.
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable
mesothelioma from the JAVELIN solid tumor phase 1b trial: safety, clinical
activity, and PD-L1 expression. Podium presentation at the ASCO Annual Meeting,
Tsai M, Untch S, Treece T, Lo Shelly, Soliman
H, PROMIS Investigators Group. The 70-gene signature provides risk
stratification and treatment guidance for patients classified as intermediate
by the 21-gene assay. Poster presentation at the ASCO Annual Meeting, June
Kelly K, Patel M, Infante JR, Iannotti N,
Leach J, Wang D, Chandler J, Arkenau HT, Taylor M, Gordon M, Wong DJ, Safran H,
Kaufman H, Keiholz U, Bajars M, von Heydebreck A, Speit I, Cuilerot JM, Gulley
JL. Avelumab (MSB0010718C; anti-PD-L1)
in patients with advanced malignancy: safety data from 1300 patients enrolled
in the phase Ib JAVELIN solid tumor trial. Poster presentation at the ASCO
Annual Meeting, June 2016.
A, Zierhut H, Baldinger S, Swenson K, Mink P, Tsai M. Why is cancer genetic
counseling underutilized by women identified as at risk for hereditary breast
cancer? Patient perceptions of barriers following a referral letter. Poster
presentation at the NSGC Annual Education Conference, Seattle, WA, September
28-Oct 1, 2016.
L, Braatz C, Lillemoe T, Finkelstein M, Krueger J, Swenson K, Tsai M, Susnik B.
Pathology and imaging findings in patients with contralateral cancer diagnosed
on preoperative staging MRI imaging. Poster presentation at the European
Society of Breast Imaging Annual Scientific Meeting, Sept 2016, Paris, France.
TJ, Susnik B, Grimm E, Kang S, Swenson KK, Krueger J, Finkelstein MJ, Tsai ML.
The association of higher tumor HER2 load with treatment response to
neoadjuvant therapy in HER2 positive breast cancer patients. Poster
presentation at the San Antonio Breast Conference, December 2016.
B, Lillemoe TJ, Tsai ML, Finkelstein MJ, Schneider L, Braatz C, Krueger J,
Swenson K, Rueth N. Predictive value of breast MRI in detecting
mammographically occult contralateral breast cancer: Can we target women more
likely to have contralateral breast cancer based on primary tumor
clinicopathologic factors? Poster presentation at the San Antonio Breast
Conference, December 2016.